Short Interest in Coya Therapeutics, Inc. (NASDAQ:COYA) Rises By 6.3%

Coya Therapeutics, Inc. (NASDAQ:COYA) was the recipient of a significant growth in short interest during the month of October. As of October 15th, there was short interest totalling 186,100 shares, a growth of 6.3% from the September 30th total of 175,000 shares. Based on an average trading volume of 50,700 shares, the short-interest ratio is currently 3.7 days. Approximately 1.3% of the company’s shares are short sold.

Coya Therapeutics Stock Down 2.6 %

NASDAQ COYA traded down $0.19 on Friday, reaching $7.04. The stock had a trading volume of 80,125 shares, compared to its average volume of 71,926. Coya Therapeutics has a 12-month low of $4.40 and a 12-month high of $10.69. The stock has a fifty day moving average price of $6.89 and a two-hundred day moving average price of $7.10. The firm has a market capitalization of $107.15 million, a price-to-earnings ratio of -10.00 and a beta of 0.58.

Coya Therapeutics (NASDAQ:COYA) last posted its earnings results on Monday, August 12th. The company reported ($0.19) earnings per share (EPS) for the quarter. The company had revenue of $3.43 million during the quarter. Sell-side analysts forecast that Coya Therapeutics will post -1.27 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the company. Chardan Capital restated a “buy” rating and issued a $14.00 target price on shares of Coya Therapeutics in a research report on Wednesday. HC Wainwright started coverage on Coya Therapeutics in a research report on Monday, September 16th. They set a “buy” rating and a $18.00 price objective for the company.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Gilbert & Cook Inc. purchased a new stake in shares of Coya Therapeutics during the second quarter worth $61,000. Renaissance Technologies LLC purchased a new stake in Coya Therapeutics during the 2nd quarter worth about $101,000. GHP Investment Advisors Inc. acquired a new stake in Coya Therapeutics in the 3rd quarter valued at about $169,000. Finally, Vanguard Group Inc. grew its position in shares of Coya Therapeutics by 772.3% during the first quarter. Vanguard Group Inc. now owns 847,490 shares of the company’s stock worth $8,407,000 after buying an additional 750,338 shares in the last quarter. Institutional investors and hedge funds own 39.75% of the company’s stock.

About Coya Therapeutics

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.